Newsroom



News

PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.



  • December 8, 2016
  • Sildenafil May Treat PH by Limiting Cells That Induce Remodeling and Inflammation
  • (Pulmonary Hypertension News) Chronic hypoxia, or the chronic lack of oxygen in lung tissue, is an important factor in the development of PH. The disease is characterized by vascular remodeling, which ultimately leads to an increase in pulmonary arterial pressure.
  •   
  • December 7, 2016
  • Many Proteins Identified in Blood of Patients with PAH-associated Congenital Heart Disease
  • (Pulmonary Hypertension News) Scientists from China have identified nearly 200 proteins that are differentially expressed in the blood of people with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) in what may be the first time.
  •   
  • Extracorporeal Support During Bilateral Sequential Lung Transplantation in Patients With Pulmonary Hypertension: Risk Factors and Outcomes.
  • (PubMed) Severity of RV dysfunction, TR, RV dilatation, increasing oxygen requirement, and increasing mPAP showed significant associations with the need for extracorporeal support during LTX in patients with PH. Extracorporeal support was associated with increased length of stay and tracheostomy but not with mortality or other complications.
  •   
  • December 6, 2016
  • Genomics lab at Madras Medical Mission to offer ‘targeted treatment’
  • (The Hindu) To offer better targeted treatment to patients and to research and identify genetic patterns, city hospital Madras Medical Mission, along with MedGenome, a genomics-based diagnostics and research company, has set up a genomics laboratory at the hospital.
  •   
  • December 5, 2016
  • Rare lung disease patients fear lengthy negotiation trend will delay access to another new therapy, putting lives at risk
  • (The Province) Canadians affected by pulmonary arterial hypertension (PAH), including those living with scleroderma, are pleased with the recent Common Drug Review (CDR) recommendation to reimburse Uptravi (selexipag). However, the community fears access to this treatment option – the third new PAH therapy approved by Health Canada in recent years – will be delayed due to a lengthy negotiation process through the pan-Canadian Pharmaceutical Alliance (pCPA). Another Health Canada-approved PAH treatment, Opsumit (macitentan), was recommended for public funding by the CDR in January 2015, yet still remains out of reach due to unsuccessful pCPA negotiations, giving patients reason to be concerned that Uptravi may follow in its path.
  •   
  • Effect of balloon pulmonary angioplasty on respiratory function in patients with chronic thromboembolic pulmonary hypertension
  • (American College of Chest Physicians) Objectives  To investigate the effect of BPA on respiratory function
  •   
  • December 2, 2016
  • Pretreating Transfused Erythrocytes with NO Prevents Pulmonary Hypertension
  • (HospiMedica) The U.S. Food and Drug Administration (FDA) allows transfusion of human RBCs that have been stored for up to 42 days. But recent studies suggest that transfusion of RBCs stored for more than 30 days may lead to elevated PH and reduced survival of the transfused cells, which can cause hypoxia and even heart failure. Each year, approximately 326,000 patients in the United States alone receive one or more RBC units that have been stored for more than 30 days.
  •   
  • Stem Cell Therapy and Idiopathic Pulmonary Fibrosis
  • (Pulmonary Hypertension News) Stem cell therapy has been shown to have the ability of regenerating damaged organs and tissues totally or partially, depending on their potential and source of extraction.
  •   
  • December 1, 2016
  • How Can We Do More to Empower Patients Who Have Pulmonary Hypertension?
  • (Pulmonary Hypertension News) In addition to living with a rare and very serious disease, there are a host of accompanying issues. I became aware of how few resources are available to those living with pulmonary hypertension. So, I wondered, how can we empower patients with pulmonary hypertension to handle those issues?
  •   
  • SteadyMed Celebrates Phenomenal People With PH During PH Awareness Month With Launch of New Informational Website and #PHenomSelf Social Media Campaign
  • (Global Newswire) BePHenomenal.com will offer expert lifestyle information customized for people with PH, including exercise videos, healthy recipes and stories from people living with PH about how they manage their condition and refuse to let PH define them. People living with PH are encouraged to visit the site and register to receive updates as new information is added.
  •   
  • Pulmonary Hypertension and Cirrhosis
  • (Pulmonary Hypertension News) The development of pulmonary hypertension by patients with cirrhosis is usually related to portal hypertension, which is typical in patients with cirrhosis and can result in PH, as explained in the study “Pulmonary Complications of Cirrhosis,” authored by Rowen K. Zetterman, MD.
  •   
  • November 30, 2016
  • Contemporary Management of Pulmonary Arterial HTN Improves Outcomes
  • (Medscape) "In contrast to the original PAH experience, the contemporary approach to this disease is based on sound basic science and clinical trial data that is sizeable," Dr. Bradley A. Maron from Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts told Reuters Health by email. "Today PAH is treatable, and clinical care strives to achieve a high benchmark of success, including remediation of symptoms."
  •   
  • November 29, 2016
  • Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
  • (PharmIWeb) "We are pleased to receive Orphan Drug Designation for RP5063, which emphasizes the significant need for new mediations for patients suffering from PAH,” said Laxminarayan Bhat, PhD, Reviva's Founder, President and Chief Executive Officer. "In conjunction with our other clinical-stage programs, this compound further enhances Reviva's value drivers.”
  •   
  • November 28, 2016
  • Lung field alters effect of BPA on respiratory function in CTEPH patients
  • (Helio) The researchers investigated how BPA affects hemodynamics, ventilator efficiency, and gas exchange in patients with CTEPH using right heart catheterization, respiratory function test, and cardiopulmonary exercise testing (CPX).
  •   
  • November 27, 2016
  • Apoptosis-based therapy to treat pulmonary arterial hypertension
  • (NCBI) In PAH, elevated pulmonary vascular resistance causes stress to the RV, and RV failure is the major cause of death in patients with PAH4.
  •   
  • November 26, 2016
  • Pulmonary Fibrosis and PAH
  • (Pulmonary Fibrosis News) In the event that PF patients develop PAH, prognosis is usually unpredictable and quite often poor. If PAH is diagnosed later, the initial course and prognosis of the pulmonary fibrosis disease may be altered or hastened.
  •   
  • November 25, 2016
  • Caregiver’s burden in pulmonary arterial hypertension: a clinical review
  • (NCBI) Caregiver’s burden is a multidimensional phenomenon affecting care-givers physically, emotionally and socially. It is critical to examine the burden of caregivers, because of the complex responsibility they have with their partners. There are relatively few studies that have examined factors linked with psychological burden amongst caregivers of pulmonary arterial hypertension (PAH) patients
  •   
  • Early Data Support Oral Anti-Fibrotic Treatment, PBI-4050, for Pulmonary Hypertension
  • (Pulmonary Hypertension News) ProMetic Life Sciences recently presented positive preclinical data on its fibrosis-targeting lead candidate, PBI-4050, showing that the drug effectively reduces pulmonary hypertension and right ventricular hypertrophy. The company also presented positive effects of PBI-4050 on cardiovascular biomarkers in patients with metabolic syndrome and type 2 diabetes.
  •   
  • November 23, 2016
  • Exercise May Help IPAH Patients by Shifting Immune System Toward Healthier Balance
  • (Pulmonary Hypertension News) Patients with IPAH commonly show local inflammation in the constricted vessels, and in some cases an altered systemic inflammatory status, with unusual levels of immune cells and circulating proteins.
  •   
  • November 22, 2016
  • Choose the Right Stove, Burn Clean: Our Lungs Will Thank You
  • (Independent Record) Yet, when the health department last looked at statistics related to lung health in Lewis and Clark County, we were dismayed to find that we have more breathing problems per capita than other parts of the state and nation.

    Editors Note:  This article relates to wood burning which is something we all must contend with during the winter months.  Chestnuts roasting by an open fire may provide a cozy scene, but for those with lung issues, it can be a problem as the particulates ad to our respiratory load.
  •   
  • November 21, 2016
  • Mitral valve disease often missed in pulmonary hypertension
  • (Family Practice News) Dyspnea in pulmonary hypertension is caused by mitral valve disease until proven otherwise, according to Paul Forfia, MD, director of pulmonary hypertension, right heart failure, and pulmonary thromboendarterectomy at Temple University, Philadelphia.
  •   
  • 5 conditions that lead to chest pain (apart from heart attacks)
  • (The Health Site) A chest pain might not always indicate a heart attack or cardiac pain. It might be signs of an underlying infection/inflammation of the lungs, spine or food pipe. Moreover, structural infection or inflammation of the heart tissues could also lead to severe chest pain. Dr Tilak Suvarna, Senior Interventional Cardiologist, Head Department of Cardiology, Asian Heart Institute, Mumbai explains about common health conditions that can cause a chest pain, which is not a cardiac pain
  •   
  • November 18, 2016
  • Who Needs a Pulmonary Function Test
  • (Carthage Press) Many factors influence PFTs: weight, age, sex, race, environmental factors, altitude and, most importantly, a patient’s effort. Respiratory care practitioners like Sara Dobkins at Mercy Carthage have two methods to measure air moving in and out of the lungs:
  •   
  • Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction
  • (JCI Insight) Inhaled nitrite is safe in PH patients and may be efficacious in PH-HFpEF and Group 3 PH primarily via improvements in left and right ventricular filling pressures and pulmonary artery compliance. The lack of change in pulmonary vascular resistance likely may limit efficacy for Group 1 patients.
  •   
  • November 17, 2016
  • Apoptosis-based therapy to treat pulmonary arterial hypertension
  • (PubMed) Pulmonary arterial hypertension (PAH) is rare, but patients who are diagnosed with this disease still suffer from a lack of satisfactory treatment strategies to prolong survival. While currently approved drugs for PAH have some benefits, these vasodilators only have limited efficacy for eliminating pulmonary vascular remodeling and reducing mortality. Thus, our laboratory has been exploring the use of aggressive drugs, which are capable of causing apoptotic cell death, to treat PAH. We have so far found that three classes of anti-tumor agents, including anthracyclines, taxanes, and proteasome inhibitors, are capable of reducing pulmonary vascular thickness in rats with PAH.
  •   
  • ProMetic's PBI-4050 shown to reduce pulmonary hypertension and lung remodeling ...
  • (PR Newswire) Dr. Jocelyn Dupuis, MD, PhD, Professor, Department of Medicine, Université de Montréal and a leader in PH from the Montreal Heart Institute research performed an extensive preclinical study to test the potential benefits of PBI-4050 on cardiac and lung fibrosis, respiratory function, and lung structural remodeling following a myocardial infarction ("MI") induced by coronary artery ligation. Beginning two weeks after the MI, the animals were treated with PBI-4050 for three weeks
  •   
  • November 16, 2016
  • New Gene Mutation Linked to Familial PAH and May Explain Why Disease Strikes Selectively
  • (Pulmonary Hypertension News) Researchers found a new mutation in a gene — called eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4)  — in members of a family with hereditary pulmonary arterial hypertension (HPAH). This mutation represents a potential “second hit” that increases the likelihood of certain family members developing the disease.
  •   
  • Patent ductus arteriosus with persistent pulmonary artery hypertension after transcatheter closure
  • (Dovepress) Some patients with borderline hemodynamic data with PDA and PAH can deteriorate or keep sustained PAH after PDA closure. The treatment of permanent closure to these patients must be cautious.
  •   
  • November 15, 2016
  • Actelion announces positive results of the MERIT study ...
  • (Pulmonary Hypertension News) In MERIT, 80 inoperable CTEPH patients were randomized 1:1 to receive either macitentan 10 mg once daily or placebo. After 16 weeks the treatment effect was a significant 16% reduction in pulmonary vascular resistance (PVR) with macitentan compared with placebo (95% CL: -30%, -1%; p=0.04 intention-to-treat (ITT)). 
  •   
  • November 14, 2016
  • Treating Blood Cells Before Transfusion May Prevent Onset of Pulmonary Hypertension
  • (Pulmonary Hypertension News) Blood transfusions, most often involving transfusions only of red blood cells, undoubtedly save thousands of lives each year. But when stocks of red blood cells run low, people often receive cells that have been stored for more than 30 days
  •   
  • Rituximab Effective Long-Term for Systemic Sclerosis
  • (MedPage Today) Over 7 years, pulmonary function was stabilized or improved in SSc patients with interstitial lung disease receiving rituximab, and the drug also helped resolve skin thickening in these patients. As well, the study showed that cessation of rituximab therapy was associated with a decline in pulmonary function, and that the drug had an acceptable safety profile.
  •   
  • November 11, 2016
  • PAH Medications, Tracleer and Opsumit, Seen to Block Fibrosis in Systemic Sclerosis in Early Study
  • (Pulmonary Hypertension News) SSc is characterized by the development of fibrosis in the skin and other organs, and abnormal blood vessels. Although different molecules have been identified as key effectors of blood vessel rearrangement in SSc, such as ET-1 and TGF-β, the mechanisms underlying these abnormalities remain poorly understood.
  •   
  • November 10, 2016
  • Anticoagulation and Aspirin as a Treatment for PAH
  • (Pulmonary Hypertension News) Watch the video.
  •   
  • November 9, 2016
  • Faster Administration of Remodulin May Help to Ease Infusion Site Pain in PAH Patients, Study Says
  • (Pulmonary Hypertension News) Although subcutaneous infusion of Remodulin (treprostinil) is an effective treatment for patients with severe pulmonary arterial hypertension (PAH), it can have undesired effects such as pain at the infusion site. But a study reports that speeding up Remodulin administration, and combining it with injection-site pain management, is an easily tolerated option that may help patients better adhere to treatment.
  •   
  • Ventavis and Nitric Oxide Both Seen to Treat Hypertension in CTEPH Patients After Surgery
  • (Pulmonary Hypertension News) General Thoracic and Cardiovascular Surgery under the title, “A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy,” — suggests that also Ventavis can be offered following surgery to CTEPH patients.
  •   

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives